Digital vasculitis: a late complication of anti-tumour necrosis factor alpha therapy

被引:3
|
作者
Mangat, Pamela [1 ]
Whittle, Samuel [2 ]
Cleland, Les
Limaye, Vidya
机构
[1] Royal Adelaide Hosp, Dept Rheumatol, Adelaide, SA 5000, Australia
[2] Queen Elizabeth Hosp, Adelaide, SA, Australia
关键词
Angiography; Anti-TNF alpha; Neuropathy; Vasculitis;
D O I
10.1007/s10067-008-1015-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Anti-tumour necrosis factor alpha therapy has led to significant advancement in the treatment of rheumatological disease. Rarely, anti-TNF alpha antagonists have been associated with vasculitis, predominantly cutaneous leukocytoclastic vasculitis. We present the first case of angiographically-confirmed digital vasculitis occurring as a late complication of etanercept therapy. Our case adds to the limited repertoire of case reports of anti-TNF alpha induced vasculitis and highlights the potential risk of this serious complication occurring up to several years after initiation of these agents.
引用
收藏
页码:1593 / 1595
页数:3
相关论文
共 50 条
  • [1] Digital vasculitis: a late complication of anti-tumour necrosis factor alpha therapy
    Pamela Mangat
    Samuel Whittle
    Les Cleland
    Vidya Limaye
    Clinical Rheumatology, 2008, 27 : 1593 - 1595
  • [2] Anti-tumour necrosis factor therapy associated with cutaneous vasculitis
    Livermore, PA
    Murray, KJ
    RHEUMATOLOGY, 2002, 41 (12) : 1450 - 1452
  • [3] Anti-tumour necrosis factor (TNF)-α therapy (etanercept)
    Maya Buch
    Arthritis Research & Therapy, 4 (1)
  • [4] Anti-tumour necrosis factor therapy in the West Midlands
    Bartram, D
    Sheeran, T
    Price, T
    Mulherin, D
    RHEUMATOLOGY, 2004, 43 (03) : 400 - 400
  • [5] Anti-tumour necrosis factor therapy in seronegative spondyloarthritis
    Swales, C
    Bowness, P
    CLINICAL MEDICINE, 2005, 5 (03) : 219 - 222
  • [6] Clinical trial outcome of anti-tumour necrosis factor alpha therapy in rheumatic arthritis
    Choy, E
    CYTOKINE, 2004, 28 (4-5) : 158 - 161
  • [7] Anti-tumour necrosis factor a therapy: can we afford it?
    Symmons, DPM
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (07) : 969 - 970
  • [8] Problems encountered during anti-tumour necrosis factor therapy
    Desai, Sheetal B.
    Furst, Daniel E.
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2006, 20 (04): : 757 - 790
  • [9] Optic neuritis occurring with anti-tumour necrosis factor α therapy
    Simsek, Ismail
    Erdem, Hakan
    Pay, Salih
    Sobaci, Gungor
    Dinc, Ayhan
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (09) : 1255 - 1258
  • [10] The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis
    Askling, Johan
    Dixon, Will
    CURRENT OPINION IN RHEUMATOLOGY, 2008, 20 (02) : 138 - 144